Cargando…

Progress of cancer research on astrocyte elevated gene-1/Metadherin (Review)

Tumor development is initiated by an accumulation of numerous genetic and epigenetic alterations that promote tumor initiation, invasion and metastasis. Astrocyte elevated gene-1 [AEG-1; also known as Metadherin (MTDH) and Lysine-rich CEACAM1 co-isolated (LYRIC)] has emerged in recent years as a pot...

Descripción completa

Detalles Bibliográficos
Autores principales: HUANG, YONG, LI, LE-PING
Formato: Online Artículo Texto
Lenguaje:English
Publicado: D.A. Spandidos 2014
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4081432/
https://www.ncbi.nlm.nih.gov/pubmed/25009642
http://dx.doi.org/10.3892/ol.2014.2231
_version_ 1782324108595298304
author HUANG, YONG
LI, LE-PING
author_facet HUANG, YONG
LI, LE-PING
author_sort HUANG, YONG
collection PubMed
description Tumor development is initiated by an accumulation of numerous genetic and epigenetic alterations that promote tumor initiation, invasion and metastasis. Astrocyte elevated gene-1 [AEG-1; also known as Metadherin (MTDH) and Lysine-rich CEACAM1 co-isolated (LYRIC)] has emerged in recent years as a potentially crucial mediator of tumor malignancy, and a key converging point of a complex network of oncogenic signaling pathways. AEG-1/MTDH has a multifunctional role in tumor development that has been found to be involved in the following signaling cascades: i) The Ha-Ras and PI3K/Akt pathways; ii) the nuclear factor-κB signaling pathway; iii) the ERK/mitogen-activated protein kinase and Wnt/β-catenin pathways; and iv) the Aurora-A kinase signaling pathway. Studies have established that AEG-1/MTDH is crucial in tumor progression, including transformation, the evasion of apoptosis, invasion, angiogenesis and metastasis. In addition, recent clinical studies have convincingly associated AEG-1/MTDH with tumor progression and poor prognosis in a number of cancer types, including hepatocellular, esophageal squamous cell, gallbladder and renal cell carcinomas, breast, non-small cell lung, prostate, gastric and colorectal cancers, and glioma, melanoma, neuroblastoma and osteosarcoma. AEG-1/MTDH may be used as a biomarker to identify subgroups of patients who require more intensive treatments and who are likely to benefit from AEG-1/MTDH-targeted therapies. The therapeutic targeting of AEG-1/MTDH may simultaneously block metastasis, suppress tumor growth and enhance the efficacy of chemotherapeutic treatments.
format Online
Article
Text
id pubmed-4081432
institution National Center for Biotechnology Information
language English
publishDate 2014
publisher D.A. Spandidos
record_format MEDLINE/PubMed
spelling pubmed-40814322014-07-09 Progress of cancer research on astrocyte elevated gene-1/Metadherin (Review) HUANG, YONG LI, LE-PING Oncol Lett Articles Tumor development is initiated by an accumulation of numerous genetic and epigenetic alterations that promote tumor initiation, invasion and metastasis. Astrocyte elevated gene-1 [AEG-1; also known as Metadherin (MTDH) and Lysine-rich CEACAM1 co-isolated (LYRIC)] has emerged in recent years as a potentially crucial mediator of tumor malignancy, and a key converging point of a complex network of oncogenic signaling pathways. AEG-1/MTDH has a multifunctional role in tumor development that has been found to be involved in the following signaling cascades: i) The Ha-Ras and PI3K/Akt pathways; ii) the nuclear factor-κB signaling pathway; iii) the ERK/mitogen-activated protein kinase and Wnt/β-catenin pathways; and iv) the Aurora-A kinase signaling pathway. Studies have established that AEG-1/MTDH is crucial in tumor progression, including transformation, the evasion of apoptosis, invasion, angiogenesis and metastasis. In addition, recent clinical studies have convincingly associated AEG-1/MTDH with tumor progression and poor prognosis in a number of cancer types, including hepatocellular, esophageal squamous cell, gallbladder and renal cell carcinomas, breast, non-small cell lung, prostate, gastric and colorectal cancers, and glioma, melanoma, neuroblastoma and osteosarcoma. AEG-1/MTDH may be used as a biomarker to identify subgroups of patients who require more intensive treatments and who are likely to benefit from AEG-1/MTDH-targeted therapies. The therapeutic targeting of AEG-1/MTDH may simultaneously block metastasis, suppress tumor growth and enhance the efficacy of chemotherapeutic treatments. D.A. Spandidos 2014-08 2014-06-05 /pmc/articles/PMC4081432/ /pubmed/25009642 http://dx.doi.org/10.3892/ol.2014.2231 Text en Copyright © 2014, Spandidos Publications http://creativecommons.org/licenses/by/3.0 This is an open-access article licensed under a Creative Commons Attribution-NonCommercial 3.0 Unported License. The article may be redistributed, reproduced, and reused for non-commercial purposes, provided the original source is properly cited.
spellingShingle Articles
HUANG, YONG
LI, LE-PING
Progress of cancer research on astrocyte elevated gene-1/Metadherin (Review)
title Progress of cancer research on astrocyte elevated gene-1/Metadherin (Review)
title_full Progress of cancer research on astrocyte elevated gene-1/Metadherin (Review)
title_fullStr Progress of cancer research on astrocyte elevated gene-1/Metadherin (Review)
title_full_unstemmed Progress of cancer research on astrocyte elevated gene-1/Metadherin (Review)
title_short Progress of cancer research on astrocyte elevated gene-1/Metadherin (Review)
title_sort progress of cancer research on astrocyte elevated gene-1/metadherin (review)
topic Articles
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4081432/
https://www.ncbi.nlm.nih.gov/pubmed/25009642
http://dx.doi.org/10.3892/ol.2014.2231
work_keys_str_mv AT huangyong progressofcancerresearchonastrocyteelevatedgene1metadherinreview
AT lileping progressofcancerresearchonastrocyteelevatedgene1metadherinreview